Table 1.

Key trials of single agent HDACi in hematologic malignancies

AgentStudyDiseasePhaseNo.Response
Vorinostat (SAHA)O'Connor et al (17)HL/DLBCL/CTCL/otherI35CR 1, PR 4, SD 3
Duvic et al (19)CTCLII33PR 8 (SS 4)
Olsen et al (20)CTCLIIb74CR 1, PR 21
Garcia-Manero et al (22)Advanced leukemia/MDSI41CR 2, CRi 2, HI 3
Romidepsin (depsipeptide)Byrd et al (32)AML/CLLI20Nil
Bates et al (35)CTCLII71CR 6, PR 24, SD 19
Kim et al (39)CTCLII92CR 7, PR 10
Piekarz et al (40)PTCLII43PR 10, CR 7
MGCD0103Garcia-Manero et al (45)Advanced leukemia/MDSI29CR 3
Lancet et al (46)Advanced leukemia/MDSI19SD 4
Bociek et al (47)HLII33CR 2, PR 6
Crump et al (48)DLBCL/FLII50CR 1, PR 4, SD 22
Panobinostat (LBH589)Giles et al (52)Advanced leukemia/MDSI15HI 1
Duvic et al (56)CTCLII95CR 4, Skin CR 2, PR
Ottmann et al (51)AML/MDS/MF/MM/HL/NHLI/II146*CR 3, CRi 1, PR 17, SD 14
Prince et al (54)NHL/solid tumorsI19*CR 2 (CTCL), PR 2 (CTCL)
Belinostat (PXD-101)Gimseng et al (59)NHL/CLL/MMI16SD 5
Entinostat (MS-275)Gojo et al (61)Advanced leukemia/MDSI38Nil
  • Abbreviations: MF, myelofibrosis; HI, hematologic response.

  • * Ongoing.